global dermatology market

The Global Dermatology Market Continues to Boom

16 March 2020
Pharma
global dermatology market

Dermatology and the drugs associated with it are big business worldwide, and only growing bigger.  As things stand, the global dermatology market is set to nearly triple in the span of a decade, from $31.6 billion in 2016 up to an estimated $83.2 billion by 2026.  This is a wide-open field ripe for investment and expansion, and worth watching for new opportunities.  

What to Expect from The Global Dermatology Market in the 2020s

Growth is coming from multiple sources. Broadly speaking, the West - particularly the United States and Europe - are leading the way in R&D, while global markets are booming as growing standards of living lead to more markets becoming receptive to purely cosmetic medical purchases.

Sales in western markets continue to grow, with the United States being the single largest market. Forecasts show the US market alone growing to over $20 billion by 2026.

Likewise, the United States is dominant in the development of new products.  Strong patent laws and high levels of investment into the pharma industry suggest the US will continue in this role for years to come.  In addition, the United States has the highest per-capita spending on medical products in general, contributing to its market domination.

Europe, on the other hand, may see stagnation or downturn.  Several countries in the region are looking at introducing cost-cutting measures which could slow down growth.

The real opportunities for the dermatology market, however, may come from newer markets, particularly the BRICS nations.  Across the board, both total and per-capita healthcare spending in BRICS has been increasing, with the dermatology market benefiting significantly from an influx of foreign-developed products.  In addition, other emerging markets such as Africa and SE Asia are also seeing rapid growth in the adoption of western cosmetic pharmaceuticals.

Currently, the only potential source of restraints on the industry come from patent expiration - which can be countered through reformulation - as well as the ever-present possibility of governments seizing patents.

All in all, the global dermatology market is booming, and will be providing numerous opportunities in the years to come.

Get Your Business Intelligence insight from Visiongain

Visiongain is one of the world leaders in business research and reporting, with thousands of detailed reports covering eighteen verticals in depth.  From technology to medicine to aerospace, we have the intelligence your company needs to succeed.

Click here to explore our range of pharmacological business reports.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever